Last reviewed 2026-06-01 · How we verify

[14C]-OPC-167832

Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase 1 active Small molecule ✓ Verified Jun 2026 Quality 10/100

[14C]-OPC-167832 is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc.. It is currently in Phase 1 development.

There is limited information available on [14C]-OPC-167832, including its modality, as it is listed as "Unknown" in ChEMBL.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	[14C]-OPC-167832
Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[14C]-OPC-167832 CI brief — competitive landscape report
[14C]-OPC-167832 updates RSS · CI watch RSS
Otsuka Pharmaceutical Development & Commercialization, Inc. portfolio CI

Frequently asked questions about [14C]-OPC-167832

What is [14C]-OPC-167832?

[14C]-OPC-167832 is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc..

Who makes [14C]-OPC-167832?

[14C]-OPC-167832 is developed by Otsuka Pharmaceutical Development & Commercialization, Inc. (see full Otsuka Pharmaceutical Development & Commercialization, Inc. pipeline at /company/otsuka-pharmaceutical-development-commercialization-inc).

What development phase is [14C]-OPC-167832 in?

[14C]-OPC-167832 is in Phase 1.

Manufacturer: Otsuka Pharmaceutical Development & Commercialization, Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing